Rigel Pharmaceuticals, Inc. (RIGL) is a leading biotechnology company focused on the discovery, development, and delivery of innovative therapies that have a profound impact on the lives of patients dealing with hematologic disorders and cancer. At Rigel, we are committed to enhancing patient lives through the development of transformative treatments.

One of our flagship products is TAVALISSE® - an oral tablet designed to address thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have not responded well to previous therapies. Additionally, we offer REZLIDHIA®, a capsule-based treatment option for relapsed or refractory acute myeloid leukemia patients with a susceptible IDH1 mutation. With a robust pipeline of potential treatments and ongoing clinical trials, Rigel Pharmaceuticals is at the forefront of medical innovation.

We value our team members and provide a supportive work environment that encourages growth and collaboration. Join us at Rigel Pharmaceuticals and contribute to our mission of improving patient outcomes